Follicular lymphoma B cells induce the conversion of conventional CD4<sup>+</sup> T cells to T‐regulatory cellsWeiyun Z. Ai, Ronald Levy, Jing‐Zhou Hou et al.|International Journal of Cancer|2008Cited by 73
Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN StudyAjay K. Gopal, Gilles Salles, Stephen J. Schuster et al.|Blood|2016Cited by 9
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapiesTae‐Min Kim, Seok‐Goo Cho, Ryan Jacobs et al.|Blood|2025Cited by 2
SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphomaChan Y. Cheah, Jing‐Zhou Hou, Monique Menzies Wojtowicz et al.|Blood|2025Cited by 1
Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AMLShukaib Arslan, Kevin Quann, Padma Sri Katikaneni et al.|Blood|2025Cited by 0